Top Midday Decliners

MT Newswires Live

2小时前

Longeveron's (LGVN) phase 2b trial of stem cell therapy laromestrocel in 40 infants with hypoplastic left heart syndrome failed to meet its primary endpoint of a change in right ventricular ejection fraction at Month 12, the company said late Wednesday.

Shares slumped 58% as intraday trading volume climbed to over 1.2 million from a daily average of about 47,000.

Viant Technology (DSP) announced late Wednesday an underwritten public offering of 8.5 million Class A shares by a selling stockholder.

Shares sank 17% as intraday trading volume soared to over 1.0 million from the stock's daily average of roughly 256,000.

Fluence Energy (FLNC) cut fiscal 2026 revenue guidance, citing ongoing supply chain issues impacting its US production. Baird downgraded Fluence to underperform from neutral and adjusted its price target to $3 from $10.

Fluence shares fell 15% as intraday trading volume climbed to over 27.4 million from a daily average of about 7.6 million.

Price: 2.83, Change: -3.85, Percent Change: -57.63

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2668699177"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2668699177\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2668699177?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-18 02:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2668699177","market":"sh","top_or_hot":-1,"title":"Top Midday Decliners","media":"MT Newswires Live","content":"<html><body><p> Longeveron's (LGVN) phase 2b trial of stem cell therapy laromestrocel in 40 infants with hypoplastic left heart syndrome failed to meet its primary endpoint of a change in right ventricular ejection fraction at Month 12, the company said late Wednesday.</p><p>Shares slumped 58% as intraday trading volume climbed to over 1.2 million from a daily average of about 47,000.</p><p>Viant Technology (DSP) announced late Wednesday an underwritten public offering of 8.5 million Class A shares by a selling stockholder.</p><p>Shares sank 17% as intraday trading volume soared to over 1.0 million from the stock's daily average of roughly 256,000.</p><p>Fluence Energy (FLNC) cut fiscal 2026 revenue guidance, citing ongoing supply chain issues impacting its US production. Baird downgraded Fluence to underperform from neutral and adjusted its price target to $3 from $10.</p><p>Fluence shares fell 15% as intraday trading volume climbed to over 27.4 million from a daily average of about 7.6 million.</p><p>Price: 2.83, Change: -3.85, Percent Change: -57.63</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Midday Decliners</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Midday Decliners\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-18 02:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Longeveron's (LGVN) phase 2b trial of stem cell therapy laromestrocel in 40 infants with hypoplastic left heart syndrome failed to meet its primary endpoint of a change in right ventricular ejection fraction at Month 12, the company said late Wednesday.</p><p>Shares slumped 58% as intraday trading volume climbed to over 1.2 million from a daily average of about 47,000.</p><p>Viant Technology (DSP) announced late Wednesday an underwritten public offering of 8.5 million Class A shares by a selling stockholder.</p><p>Shares sank 17% as intraday trading volume soared to over 1.0 million from the stock's daily average of roughly 256,000.</p><p>Fluence Energy (FLNC) cut fiscal 2026 revenue guidance, citing ongoing supply chain issues impacting its US production. Baird downgraded Fluence to underperform from neutral and adjusted its price target to $3 from $10.</p><p>Fluence shares fell 15% as intraday trading volume climbed to over 27.4 million from a daily average of about 7.6 million.</p><p>Price: 2.83, Change: -3.85, Percent Change: -57.63</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4096","symbol_name":"电气部件与设备","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2668699177","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2668699177","pubTimestamp":1789670197,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Longeveron's  phase 2b trial of stem cell therapy laromestrocel in 40 infants with hypoplastic left heart syndrome failed to meet its primary endpoint of a change in right ventricular ejection fraction at Month 12, the company said late Wednesday.Shares slumped 58% as intraday trading volume climbed to over 1.2 million from a daily average of about 47,000.Viant Technology  announced late Wednesday an underwritten public offering of 8.5 million Class A shares by a selling stockholder.Shares sank 17% as intraday trading volume soared to over 1.0 million from the stock's daily average of roughly 256,000.Fluence Energy  cut fiscal 2026 revenue guidance, citing ongoing supply chain issues impacting its US production. Baird downgraded Fluence to underperform from neutral and adjusted its price target to $3 from $10.Fluence shares fell 15% as intraday trading volume climbed to over 27.4 million from a daily average of about 7.6 million.Price: 2.83, Change: -3.85, Percent Change: -57.63","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4096":"电气部件与设备","LU0823414478.USD":"法巴经典能源转换基金","FLNC":"Fluence Energy, Inc.","LGVN":"Longeveron Inc","LU2249611893.SGD":"BNP PARIBAS ENERGY TRANSITION \"CRH\" (SGD) ACC","LU2506951792.HKD":"BNP PARIBAS ENERGY TRANSITION \"CRH\" (HKDHDG)       ACC","LU2294711713.HKD":"BNP PARIBAS ENERGY TRANSITION \"C\" (HKD) ACC","LU0823414551.USD":"BNP PARIBAS ENERGY TRANSITION \"C\" (USD) INC","BK4023":"应用软件","DSP":"Viant Technology Inc.","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU2357125470.USD":"BNP PARIBAS ENERGY TRANSITION \"CLASSIC RH\" (USDHDG) ACC","BK4139":"生物科技"},"translate_title":"午盘跌幅最大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LGVN":1,"FLNC":1,"DSP":1},"content_text":"Longeveron's (LGVN) phase 2b trial of stem cell therapy laromestrocel in 40 infants with hypoplastic left heart syndrome failed to meet its primary endpoint of a change in right ventricular ejection fraction at Month 12, the company said late Wednesday.Shares slumped 58% as intraday trading volume climbed to over 1.2 million from a daily average of about 47,000.Viant Technology (DSP) announced late Wednesday an underwritten public offering of 8.5 million Class A shares by a selling stockholder.Shares sank 17% as intraday trading volume soared to over 1.0 million from the stock's daily average of roughly 256,000.Fluence Energy (FLNC) cut fiscal 2026 revenue guidance, citing ongoing supply chain issues impacting its US production. Baird downgraded Fluence to underperform from neutral and adjusted its price target to $3 from $10.Fluence shares fell 15% as intraday trading volume climbed to over 27.4 million from a daily average of about 7.6 million.Price: 2.83, Change: -3.85, Percent Change: -57.63","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}